Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
ACQUIRED COMPANY
 
My Lists

Oculex Pharmaceuticals  (Stock symbol: OCLX ) Acquired by Allergan (2003 $ 230,000,000)

601 West California Avenue
Sunnyvale, CA 94086
USA
(408)-481-0424
Website Company Summary Management Team
Board

Outside board: (May no longer be on the board) Joel Kellman (GGV Capital Managing Partner);  Steve Elms (Perseus-Soros Biopharmaceutical Fund);  Carl Goldfischer (Bay City Capital) Lester Kaplan (Allergan(x) President);  Frank Kung (Vivo Capital) Song Tjoa (Greatland Company)
Former outside board: Thomas Ng (Venture TDF)
Company

Business description: Oculex Pharmaceuticals is a leading ophthalmic drug delivery company that has created a novel and proprietary platform technology to facilitate the treatment of major sight-threatening eye diseases and conditions. Its proprietary drug delivery system is the first biodegradable, sustained-release system designed to deliver drugs directly into the eye.
Partners include: Allergan
Capital

Rounds: 2
Recent Fundings: Oct 2002
Capital raised: 93.5M
Last Round: 3.5M
Ownership: Acquired by Allergan (2003 $ 230,000,000)
Stock Symbol: OCLX

Last Tweets


 

Last Mentions


Overview
Record updated: Jan 2005
Sector: Biotech
Year Founded: 1993
Headcount: 26-50
Rounds: 2
Recent Fundings: Oct 2002
Capital Raised: 93.5M
Last Round: 3.5M
Ownership: Acquired by Allergan (2003 $ 230,000,000)
Stock Symbol: OCLX